[A21-13] Inclisiran (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V
Last updated 03.05.2021
Project no.:
A21-13
Commission:
Commission awarded on 01.02.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia
Patients in whom dietary and drug options for lipid lowering have not been exhausted: added benefit not proven. Patients in whom dietary and drug options for lipid lowering (except evolocumab) have been exhausted: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.